Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) was the recipient of unusually large options trading on Wednesday. Traders acquired 1,002 put options on the stock. This represents ...

If you suffered losses exceeding $50,000 in Maravai LifeSciences between August 7, 2024 and February 24, 2025 and would like ...

Nucleic Acid Production revenue was $41.9 million for the fourth quarter, representing a 28.8% decrease year-over-year. The revenue decrease was primarily from large GMP orders in 2023 not recurring ...

The stock market is in a bit of a tailspin of late as investors worry about the future of the economy. It can be a great idea ...

Represents additional corporate income taxes at an assumed effective tax rate of approximately 24% applied to additional net loss attributable to Maravai LifeSciences Holdings, Inc. from the ...

Maravai LifeSciences Holdings (NASDAQ:MRVI) is scheduled to announce Q4 earnings results on Tuesday, March 18th, after market close. The consensus EPS Estimate is -$0.04 (+95.0% Y/Y) and the consensus ...

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has ...

Maravai LifeSciences Holdings, Inc.’s MRVI share price has surged by 10.86%, which has investors questioning if this is right time to sell.

Maravai LifeSciences Holdings LLC SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services ...

"Our fourth-quarter revenue landed near the midpoint of our guidance range, with the BST segment outperforming and NAP coming in slightly lower," said Trey Martin, CEO, Maravai LifeSciences.

"Our fourth-quarter revenue landed near the midpoint of our guidance range, with the BST segment outperforming and NAP coming in slightly lower," said Trey Martin, CEO, Maravai LifeSciences.